# US 2022/0033452 A1 · Polypeptide derived from cap1 and pharmaceutical composition comprising same as effective ingredient

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033452 A1
- Document ID: US20220033452A1
- Status: Published application
- Kind: A1
- Application number: 17/368,090
- Filed: 2021-07-06
- Published: 2022-02-03
- Earliest claimed: 2017-01-31
- Assignees: Seoul National University Hospital
- Applicants: Seoul National University Hospital
- Inventors: Hyo Soo KIM; Hyun Duk JANG; Sang Eun LEE
- Web page: https://patentgrep.com/patent/US20220033452A1

## CPC

- C07K 14/4703: {Inhibitors; Suppressors}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/70: containing domain for protein-protein interaction
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to a polypeptide derived from CAP1 and a pharmaceutical composition comprising the same as an effective ingredient and, more particularly, to a peptide including the amino acid sequence of SEQ ID NO: 1, any 0 to 20 amino acid residues added to the N terminus thereof, and any 0 to 75 amino acid residues added to the C terminus thereof, and a pharmaceutical composition comprising the peptide as an effective ingredient for the prevention and alleviation of inflammatory diseases, the inhibition of cancer and cancer metastasis, the prevention and alleviation of diabetes, fatty hepatitis, arteriosclerosis, cardiovascular diseases, and heart failure. Exhibiting the effect of suppressing the binding of resistin to CAP1 and inhibiting NF-kB activity, the method of the present invention can be useful for treating inflammatory diseases, cancer, diabetes, fatty hepatitis, arteriosclerosis, cardiovascular diseases, and heart failure which are caused by the activation of resistin and NF-kB.

## Claims

### Claim 1

A method for treating an inflammatory disease, cancers, diabetes, fatty hepatitis, atherosclerosis, cardiovascular disorders, or a heart failure in a subject in need thereof, the method comprising administering a composition comprising a peptide consisting of SEQ ID NO: 1 (GPPPPPVSTS), SEQ ID NO: 2 (PPPPGPPPPPVSTSSGSDES), SEQ ID NO: 4 (AAAAGPPPPPVSTSSGSDES), or SEQ ID NO: 5 (PPPPGAAAAAVSTSSGSDES) as an active ingredient to the subject in an amount effective for treating the following diseases: inflammatory diseases, cancers, diabetes, fatty hepatitis, atherosclerosis, cardiovascular disorders, and heart failure.

### Claim 2 (depends on 1)

The method of claim 1, wherein the peptide inhibits the binding of adenylyl cyclase associated protein 1 (CAP1) and resistin.

### Claim 3 (depends on 2)

The method of claim 2, wherein the inhibition of the binding is a competitive inhibition.

### Claim 4 (depends on 1)

The method of claim 1, wherein the peptide inhibits the activity of an inflammatory cytokine.

### Claim 5 (depends on 1)

The method of claim 1, wherein the peptide inhibits the activity of nuclear factor kappa B (NF-κB).

### Claim 6 (depends on 1)

The method of claim 1, wherein the peptide induces the activity of AMP activated protein kinase (AMPK).

### Claim 7 (depends on 1)

The method of claim 1, wherein the peptide inhibits the activity of protein kinase A (PKA).

### Claim 8 (depends on 1)

The method of claim 1, wherein the cancer is at least one selected from the group consisting of breast cancer, colorectal cancer, lung cancer, small cell lung cancer, gastric cancer, liver cancer, blood cancer, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, cutaneous or intraocular melanoma, eye tumor, peritoneal cancer, uterine cancer, ovarian cancer, rectal cancer, anal cancer, colon cancer, fallopian tube carcinoma, endometrial carcinoma, cervical cancer, vaginal cancer, vulvar carcinoma, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine cancer, thyroid cancer, parathyroid carcinoma, adrenal cancer, soft tissue sarcoma, urethral cancer, penis cancer, prostate cancer, testicular cancer, oral cancer, gallbladder cancer, cholangiocarcinoma, chronic or acute leukemia, lymphocyte lymphoma, bladder cancer, kidney cancer, ureteral cancer, renal cell carcinoma, renal pelvic carcinoma, CNS tumor, primary CNS lymphoma, spinal cord tumor, brain stem glioma, and pituitary adenoma.

### Claim 9 (depends on 1)

The method of claim 1, wherein the inflammatory disease is at least one selected from the group consisting of atopic dermatitis, psoriasis, sinusitis, rhinitis, conjunctivitis, asthma, dermatitis, inflammatory collagen vascular disease, glomerulonephritis, encephalitis, inflammatory bowel disease, chronic obstructive pulmonary disease, sepsis, septic shock, pulmonary fibrosis, undifferentiated spondylarthrosis, undifferentiated arthropathy, arthritis, inflammatory osteolysis, chronic inflammatory diseases caused by viral or bacterial infection, colitis, ulcerative colitis, inflammatory bowel disease, type 1 diabetes, type 2 diabetes, arthritis, rheumatoid arthritis, reactive arthritis, osteoarthritis, psoriasis, scleroderma, osteoporosis, atherosclerosis, myocarditis, endocarditis, pericarditis, cystic fibrosis, Hashimoto thyroiditis, Graves' disease, leprosy, syphilis, Lyme disease, borreliosis, neurogenic borreliosis, tuberculosis, sarcoidosis, lupus, discoid lupus, chilblain lupus, lupus nephritis, systemic lupus erythematosus, macular degeneration, uveitis, irritable bowel syndrome, Crohn's disease, Sjogren's syndrome, fibromyalgia, chronic fatigue syndrome, chronic fatigue and immune dysfunction syndrome, myalgic encephalomyelitis, amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis.

### Claim 10 (depends on 1)

The method of claim 1, wherein the cardiovascular disease is at least one selected from the group consisting of hypertension, ischemic heart disease, coronary artery disease, angina pectoris, myocardial infarction, stroke, and Arrhythmia.
